The IDH mutation confers a significant survival benefit to patients with glioma, even in the most aggressive grade 4 astrocytomas (31 months overall survival vs. 15 months survival).6 As all gliomas inevitably recur, longitudinal monitoring is essential to enable early detection of tumor recurrence. Here, IDH1 is linked to central nervous system cancer.